zurück

Tepotinib (non-small cell lung cancer (NSCLC), METex14-skipping mutation, pre-treated patients)

Subject:

  • Active Substance: Tepotinib
  • Name: Tepmetko®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Merck Europe B.V. 

Time table:

  • Start: 01.03.2022
  • Final decision by G-BA: 01.09.2022

Final decision:

  • Patients with a PD-1/PD-L1 antibody monotherapy as first line therapy: No additional benefit proved
  • Patients with a platinum-containing chemotherapy as first line therapy: No additional benefit proved
  • Patients with either a PD-1/PD-L1 antibody in combination with a platinum-containing chemotherapy or a sequential therapy with a PD-1/PD-L1 antibody and a platinum-containing chemotherapy as first line therapy: No additional benefit proved